Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic

Inclusion Criteria

• •Provision of written informed consent for study participation before initiation of any study related procedures, signed by the patient's legal guardian
• •Female and/or male, aged between 18 and 60 years (inclusive)
• •Is hospitalised in a psychiatric unit with an acute episode of schizophrenia defined by CCMD-3 criteria as one of the following: \[20.1\] paranoid schizophrenia, \[20.2\] hebephrenic schizophrenia, \[20.3\] catatonic schizophrenia, \[20.5\] undifferentiated schizophrenia